Reuters logo
Novartis's drug reduces heart failure deaths: study
September 24, 2012 / 5:35 AM / 5 years ago

Novartis's drug reduces heart failure deaths: study

ZURICH (Reuters) - Novartis’s investigational medicine RLX030 reduced the number of deaths in patients with acute heart failure, the drugmaker said on Monday based on the results of a late-stage trial.

RLX030 is form of the human hormone relaxin-2. Serelaxin acts by relaxing the blood vessels, leading to reduced stress on the heart and kidneys, the firm said in a statement.

Reporting by Catherine Bosley

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below